A new blood test detected early-stage pancreatic cancer with 87.5% accuracy in a study of 672 people. The test combines four ...

At present, doctors often rely on a blood test called CA 19-9 to monitor pancreatic cancer. However, this test is not very reliable for early detection because levels usually rise only after the ...

New @hopkinskimmel research finds extra copies of chromosome 1q may drive the earliest stages of pancreatic cancer. › ...

A team of scientists from Duke Health has made an important discovery that could help detect pancreatic cancer earlier. They ...

Novocure NVCR-0.22%decrease; red down pointing triangle said the Food and Drug Administration approved its Optune Pax product to treat people with certain pancreatic cancers. The drug can be used for ...

FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally advanced pancreatic cancer, in combination with gemcitabine and nab-paclitaxel.

FDA approved Optune Pax for locally advanced pancreatic cancer with gemcitabine/nab-paclitaxel, marking the first new modality in decades for this nonresectable ...

Through non-invasive, wearable arrays, Optune Lua uses TTFields to exert physical forces on the electrically charged components of the dividing cancer cells. [Image courtesy of Novocure] Novocure ...

Notoriously tricky to detect, pancreatic cancer also often resists traditional therapy. So, researchers are urgently looking for new ways to disrupt tumor formation. Though scientists know that the ...